ACACIA PHARMA

Acacia Pharma Ltd., a pharmaceutical company, discovers and develops supportive care drugs. The company focuses on cancer supportive care. Its products include APD405, an injectable formulation of an oral drug for the use of nausea and vomiting; APD209, which is for the use of cancer cachexia; and APD421, an intravenous formulation for the use of prevention and treatment of nausea and vomiting. The company also concentrates its discovery efforts in cancer related fatigue, cancer cachexia, and xerostomia. Acacia Pharma Ltd. was incorporated in 2006 and is based in Cambridge, United Kingdom.